BRPI0813629A2 - derivados de pirimidina úteis no tratamento de condições inflamatórias ou alérgicas - Google Patents
derivados de pirimidina úteis no tratamento de condições inflamatórias ou alérgicasInfo
- Publication number
- BRPI0813629A2 BRPI0813629A2 BRPI0813629A BRPI0813629A BRPI0813629A2 BR PI0813629 A2 BRPI0813629 A2 BR PI0813629A2 BR PI0813629 A BRPI0813629 A BR PI0813629A BR PI0813629 A BRPI0813629 A BR PI0813629A BR PI0813629 A2 BRPI0813629 A2 BR PI0813629A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidine derivatives
- treating inflammatory
- derivatives useful
- allergic conditions
- allergic
- Prior art date
Links
- 206010027654 Allergic conditions Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07113237 | 2007-07-26 | ||
| PCT/EP2008/059748 WO2009013348A2 (en) | 2007-07-26 | 2008-07-24 | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0813629A2 true BRPI0813629A2 (pt) | 2018-07-10 |
Family
ID=38942282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0813629A BRPI0813629A2 (pt) | 2007-07-26 | 2008-07-24 | derivados de pirimidina úteis no tratamento de condições inflamatórias ou alérgicas |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP2173722B1 (pt) |
| JP (1) | JP5485884B2 (pt) |
| KR (1) | KR20100025006A (pt) |
| CN (1) | CN101765591B (pt) |
| AR (1) | AR067869A1 (pt) |
| AU (1) | AU2008278966B2 (pt) |
| BR (1) | BRPI0813629A2 (pt) |
| CA (1) | CA2694275A1 (pt) |
| CL (1) | CL2008002185A1 (pt) |
| CO (1) | CO6290670A2 (pt) |
| CR (1) | CR11208A (pt) |
| EA (1) | EA201000104A1 (pt) |
| EC (1) | ECSP109900A (pt) |
| ES (1) | ES2394126T3 (pt) |
| MA (1) | MA31594B1 (pt) |
| MX (1) | MX2010001020A (pt) |
| PE (1) | PE20090880A1 (pt) |
| SV (1) | SV2010003464A (pt) |
| TN (1) | TN2010000038A1 (pt) |
| TW (1) | TW200909426A (pt) |
| WO (1) | WO2009013348A2 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8268834B2 (en) * | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| GB0815947D0 (en) | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
| CA2755285C (en) | 2009-03-20 | 2014-02-11 | Yunxin Y. Bo | Inhibitors of pi3 kinase |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| JP4967004B2 (ja) * | 2009-09-14 | 2012-07-04 | 東京エレクトロン株式会社 | レジスト塗布現像装置およびレジスト塗布現像方法 |
| WO2015108861A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US10112926B2 (en) | 2014-04-24 | 2018-10-30 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
| EP3134397A1 (en) | 2014-04-24 | 2017-03-01 | Novartis AG | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| PL3134395T3 (pl) * | 2014-04-24 | 2018-07-31 | Novartis Ag | Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu |
| CN112088157B (zh) * | 2017-12-22 | 2023-12-26 | 拉文纳制药公司 | 作为磷脂酰肌醇磷酸激酶抑制剂的芳基-联吡啶胺衍生物 |
| MD3762368T2 (ro) | 2018-03-08 | 2022-07-31 | Incyte Corp | Compuși diol aminopirazină ca inhibitori ai PI3K-Y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038955A1 (es) * | 1996-12-05 | 2005-02-02 | Amgen Inc | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso |
| ATE293962T1 (de) * | 2000-02-25 | 2005-05-15 | Hoffmann La Roche | Adenosin-rezeptor modulatoren |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| EP1412327A2 (en) * | 2001-05-30 | 2004-04-28 | LG Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| AUPR688101A0 (en) * | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| TWI330183B (pt) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| AU2002950853A0 (en) * | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
| EP1546115A4 (en) * | 2002-09-27 | 2010-08-04 | Merck Sharp & Dohme | Substituted pyrimidines |
| ATE527250T1 (de) * | 2002-11-21 | 2011-10-15 | Novartis Ag | 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs |
| SI2316831T1 (sl) * | 2002-11-21 | 2013-07-31 | Novartis Ag | 2-(morfolin-4-il)pirimidini kot inhibitorji fosfotidilinozitol (PI) 3-kinaze in njihova uporaba pri zdravljenju raka |
| RS53118B (sr) * | 2003-02-26 | 2014-06-30 | Sugen Inc. | Aminoheteroaril jedinjenja kao inhibitori protein kinaze |
| SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| EP1641535A4 (en) * | 2003-06-30 | 2008-05-14 | Merck & Co Inc | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS |
| ES2229928B1 (es) * | 2003-10-02 | 2006-07-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirimidin-2-amina. |
| EP2264033A1 (en) * | 2004-07-27 | 2010-12-22 | SGX Pharmaceuticals, Inc. | 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS |
| SE0402735D0 (sv) * | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| WO2006099231A1 (en) * | 2005-03-10 | 2006-09-21 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
| WO2007111904A2 (en) * | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
| GB0608820D0 (en) * | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
| GB0610242D0 (en) * | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| RU2009106722A (ru) * | 2006-07-28 | 2010-09-10 | Новартис АГ (CH) | 2,4-замещенные хиназолины в качестве ингибиторов липидной киназы |
| ES2549862T3 (es) * | 2006-08-30 | 2015-11-02 | Cellzome Limited | Derivados de triazol como inhibidores de quinasa |
| CL2008001933A1 (es) * | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
-
2008
- 2008-07-24 AU AU2008278966A patent/AU2008278966B2/en not_active Expired - Fee Related
- 2008-07-24 EA EA201000104A patent/EA201000104A1/ru unknown
- 2008-07-24 ES ES08775347T patent/ES2394126T3/es active Active
- 2008-07-24 WO PCT/EP2008/059748 patent/WO2009013348A2/en not_active Ceased
- 2008-07-24 KR KR1020107001657A patent/KR20100025006A/ko not_active Abandoned
- 2008-07-24 CN CN2008801002897A patent/CN101765591B/zh active Active
- 2008-07-24 MX MX2010001020A patent/MX2010001020A/es not_active Application Discontinuation
- 2008-07-24 BR BRPI0813629A patent/BRPI0813629A2/pt not_active IP Right Cessation
- 2008-07-24 PE PE2008001259A patent/PE20090880A1/es not_active Application Discontinuation
- 2008-07-24 JP JP2010517408A patent/JP5485884B2/ja active Active
- 2008-07-24 EP EP08775347A patent/EP2173722B1/en active Active
- 2008-07-24 CA CA2694275A patent/CA2694275A1/en not_active Abandoned
- 2008-07-25 CL CL2008002185A patent/CL2008002185A1/es unknown
- 2008-07-25 TW TW097128507A patent/TW200909426A/zh unknown
- 2008-07-28 AR ARP080103260A patent/AR067869A1/es not_active Application Discontinuation
-
2010
- 2010-01-08 CR CR11208A patent/CR11208A/es not_active Application Discontinuation
- 2010-01-22 TN TNP2010000038A patent/TN2010000038A1/fr unknown
- 2010-01-25 CO CO10007032A patent/CO6290670A2/es not_active Application Discontinuation
- 2010-01-26 SV SV2010003464A patent/SV2010003464A/es not_active Application Discontinuation
- 2010-01-26 EC EC2010009900A patent/ECSP109900A/es unknown
- 2010-02-05 MA MA32591A patent/MA31594B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201000104A1 (ru) | 2010-08-30 |
| EP2173722A2 (en) | 2010-04-14 |
| AR067869A1 (es) | 2009-10-28 |
| JP5485884B2 (ja) | 2014-05-07 |
| PE20090880A1 (es) | 2009-08-06 |
| CR11208A (es) | 2010-02-12 |
| ES2394126T3 (es) | 2013-01-22 |
| CN101765591B (zh) | 2013-11-27 |
| WO2009013348A3 (en) | 2009-07-23 |
| AU2008278966A1 (en) | 2009-01-29 |
| CA2694275A1 (en) | 2009-01-29 |
| JP2010534634A (ja) | 2010-11-11 |
| WO2009013348A2 (en) | 2009-01-29 |
| CO6290670A2 (es) | 2011-06-20 |
| EP2173722B1 (en) | 2012-08-29 |
| SV2010003464A (es) | 2010-05-21 |
| MX2010001020A (es) | 2010-03-01 |
| KR20100025006A (ko) | 2010-03-08 |
| TW200909426A (en) | 2009-03-01 |
| AU2008278966B2 (en) | 2012-02-23 |
| TN2010000038A1 (en) | 2011-09-26 |
| CN101765591A (zh) | 2010-06-30 |
| ECSP109900A (es) | 2010-02-26 |
| MA31594B1 (fr) | 2010-08-02 |
| CL2008002185A1 (es) | 2009-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301339I2 (nl) | L-lysinezout van seladelpar, in het bijzonder seladelpar-L-lysinedihydraat | |
| BRPI0922095A2 (pt) | derivados de piridina e pirimidina como inibidores de fosfodiesterase 10 | |
| BRPI0921598A2 (pt) | derivados de piridina e pirimidina como inibidores de fosfodiesterase 10 | |
| BRPI0815588A2 (pt) | Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano | |
| BRPI0907435A2 (pt) | Derivados de 5-flúor pirimidina | |
| BRPI0914544A2 (pt) | derivados de pirimidona substituídos | |
| BRPI0810813A2 (pt) | Agentes anti-hipertensivos de ação dupla | |
| BRPI1015262A2 (pt) | inibidores de pl3 quinase e/ou motor | |
| BRPI0820544A2 (pt) | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase | |
| BRPI0813707A2 (pt) | Derivados de pirimidinil-piridazinona | |
| BRPI0809992A2 (pt) | Derivados de pirrolopirimidina | |
| BRPI0820113A2 (pt) | Derivados de isoxazolo-piridazina | |
| BRPI0810202A2 (pt) | Derivados de piridina | |
| BRPI0812155A2 (pt) | derivados de espiroindolinona | |
| BRPI0814236A2 (pt) | Derivados de quinazolinamida | |
| BRPI0812518A2 (pt) | Derivados de indazolamida | |
| DE602007004689D1 (de) | Persönlicher Domänen-Controller | |
| BRPI0820649A2 (pt) | Derivados de isoxazalo-pirazina | |
| BRPI0920496A2 (pt) | derivados substituídos de pirimidina etriazina | |
| HRP20141261T1 (xx) | Spojevi tioninija i njihove uporabe | |
| BRPI0816836A2 (pt) | Composições de limpeza e/ou tratamento | |
| BRPI0809971A2 (pt) | Derivados de piridina e pirimidina como antagosnistas de mglur2 | |
| BRPI0811115A2 (pt) | Compostos de heteroarilamida pirimidona | |
| DK2081950T3 (da) | Med irinotecanbehandling forbundne ekspressionsprofiler | |
| BRPI0817190A2 (pt) | Uso de nanopartículas em explosivos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law | ||
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2480 DE 17-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |